Onconetix, Inc.
ONCO · XNASCIK 1782107fmd_0SS68XDX7M28B116EXY2NY87QAManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2021 to Jun 30, 2026, 22 periods
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating revenues (regulated and unregulated) | – | – | 0 | – | – |
| Total revenues | – | – | – | 3 | 1 |
| Cost of revenue | – | – | 1 | 1 | 0 |
| Gross profit | – | – | (1) | 1 | 1 |
| Research and development | 1 | 4 | 2 | 0 | – |
| Selling, general and administrative | – | 9 | 15 | 11 | 7 |
| Total operating expenses | 3 | 13 | 35 | 58 | 18 |
| Compensation and benefits | – | – | 0 | – | – |
| Operating income | (3) | (13) | (36) | (56) | (18) |
| Interest expense | – | – | 1 | 1 | 1 |
| Interest and investment income | – | – | – | 0 | 0 |
| Other non-operating income (expense) | – | 0 | (1) | (3) | 4 |
| Income before taxes | – | (13) | (37) | (60) | (14) |
| Income tax expense | 675,730 | 3,158,873 | (0) | (1) | 0 |
| Net income from continuing operations | – | (3,158,886) | (37) | (59) | (14) |
| Net income | (3) | (13) | (37) | (59) | (14) |
| Net income to common shareholders | (4) | (14) | (37) | (59) | (16) |